Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05556824 · ClinicalTrials.gov registry record · Phase 2

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

A Phase 2 study of Gastroesophageal Reflux, sponsored by Microbiome Health Sciences.

Recruiting
Registry status
Phase 2
Development phase
247
Enrollment target
18
Study locations

NCT05556824 is a Phase 2 study of Gastroesophageal Reflux that is actively recruiting participants, run by Microbiome Health Sciences. The registered enrollment target is 247 participants, above the 175-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (41% higher). The trial reports 18 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05556824, a Phase 2 study of Gastroesophageal Reflux, is actively recruiting participants, sponsored by Microbiome Health Sciences.

RECRUITING
Registry status
Phase 2
Development phase
247 participants
Enrollment target
18
Study locations

Study Summary

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.

Conditions Studied

Gastroesophageal Reflux

Interventions

  • OTHER Placebo
  • DRUG MHS-1031

Study Locations (18)

Florida

  • Wr-Msra, Llc - Lake City
  • A Positive Clinical Research - Miami
  • Advanced Gastroenterology Associates LLC - Palm Harbor
  • Health Synergy Clinical Research - West Palm Beach
  • West Palm Quality Research (WPQR) - West Palm Beach

Virginia

  • University of Virginia Health System - Charlottesville
  • Charlottesville Medical Research Center - Charlottesville
  • Digestive Disease and Liver Specialists - Norfolk
  • GI Research Partners, LLC - Richmond

Georgia

  • EmVenio-Georgia (EMGA) - Atlanta
  • WR-Mount Vernon Clinical Research (MVCR) - Sandy Springs

Texas

  • SMS Clinical Research (SMSR) - Mesquite
  • A and U Family Medicine (NCR) - Sugar Land

Arizona

  • Elite Clinical Studies LLC - Phoenix

California

  • Angel City Research - Los Angeles

Michigan

  • Gastroenterology Associates of Western Michigan PLC (WMCR) - Wyoming

North Carolina

  • M3 Wake Research (CPOR) - Raleigh

Trial Details

FieldValue
Enrollment Target 247 participants
Start Date 2023-03-03
Est. Completion 2026-03
Phase Phase 2

Sponsor

Microbiome Health Sciences

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05556824

The ClinicalTrials.gov registry entry for NCT05556824 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 175-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (41% higher). The listed sponsor is Microbiome Health Sciences, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05556824 reports 18 study locations spanning 9 distinct geographic areas - top geographies include Florida, Virginia, Georgia.

Frequently Asked Questions

What is clinical trial NCT05556824 about?

NCT05556824 is a clinical study titled "Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD". This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.

What is the current status of trial NCT05556824?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2023-03-03. Estimated completion is 2026-03.

What conditions does trial NCT05556824 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux.

What interventions are being tested in trial NCT05556824?

The interventions under investigation include: Placebo (OTHER), MHS-1031 (DRUG).

Who is sponsoring clinical trial NCT05556824?

This trial is sponsored by Microbiome Health Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05556824 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroesophageal Reflux

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastroesophageal Reflux

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.